Tungsten Mining (ASX: TGN) has unveiled a strong pre-feasibility study for its 100%-owned Mt Mulgine Tungsten Project in ...

The phase 1b/2 ELEVATE study evaluated everolimus, an mTORC1 inhibitor, plus elacestrant, a next-generation, oral selective ER degrader, in adult patients with ER+/HER2- breast cancer.

Over the past seven months, American Rare Earths Limited ('ARR' or the 'Company') has continued to advance Halleck Creek from a resource-stage ...

Researchers evaluated the long-term use of acalabrutinib monotherapy in patients with treatment-naïve or relapsed Waldenström macroglobulinemia.

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic ...

CMS recently issued its proposed 2027 Medicare Physician Fee Schedule.The proposed schedule includes a 0.75% increase to the ...

The percentage of oral targeted anticancer drugs used for indications with label-documented evidence of survival benefit ...

A fallen Okolona firefighter will be honored with a street sign as departments improve cancer safety measures.

ASX lithium developers are moving towards production as a potential supply gap puts a premium on projects that can deliver ...

Although he typically prefers to minimize time spent in the hospital and has an hour-long commute to the academic center, he understands that CAR T-cell therapy requires treatment at a specialized ...

Researchers evaluated rituximab maintenance after ibrutinib-containing therapy in younger patients with untreated MCL.

"UK MHRA grants approval for Scancell's Phase III study of iSCIB1+" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. Florin Anghel, 27, and Tita Istrate, 24, ...